OMER vs TVTX
OMER: A clinical-stage biotech company commercializing complement-pathway inhibitors for rare hematologic and immune diseases, with FDA-approved YARTEMLA for stem cell transplant complications and a $240M asset sale of its lead MASP-3 program to Novo Nordisk. TVTX: A biopharmaceutical company developing and commercializing innovative therapies to address rare kidney and metabolic diseases with high unmet need.
Side-by-side fundamentals
| Metric | OMER | TVTX | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $19.27 | $65.71 | |
| Market cap as of 2026-08-24 | $1.4B | $6.2B | |
| P/E as of 2026-08-24 | 14.37 | n/a | |
| PEG as of 2026-08-24 | n/a | 1.04 | |
| Net margin as of 2026-08-24 | +566.7% | -7.3% | OMER higher |
| Gross margin as of 2026-08-24 | +94.1% | +98.6% | TVTX higher |
| Operating margin as of 2026-08-24 | -176.1% | -6.8% | TVTX higher |
| ROE as of 2026-08-24 | +107.5% | -55.8% | OMER higher |
| ROA as of 2026-08-24 | +34.5% | -7.0% | OMER higher |
| Debt / equity as of 2026-08-24 | 21.55 | 24.58 | OMER lower |
| Revenue growth (YoY) as of 2026-08-24 | n/a | +77.1% | |
| Revenue CAGR (3y) SEC XBRL | +4.4% | +64.9% | TVTX higher |
| Beta as of 2026-08-24 | 2.61 | 1.11 | |
| 1-year return as of 2026-08-21 close | +330.1% | +269.4% | OMER higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.